The rapidly developing mass spectrometry-based proteomics is indispensable for precision medicine. However, its penetration into clinic has yet to prevail. One technical bottleneck is high throughput proteomic analysis of clinical specimens from (multi-center) cohort studies, whereas integrative analysis of proteomics data with clinical and other omics data poses another technical challenge. Moreover, the comprehension of the unmet clinical needs by the mass spectrometrists, and the understanding of the progresses and limitations of cutting-edge proteomic techniques by the clinicians are non-trivial. This symposium gathers experts from clinical medicine, proteomics and beyond, with a goal of building a complete picture of the MS-based clinical proteomics: the current status and the perspective for future development.
The rapidly developing mass spectrometry-based proteomics is indispensable for precision medicine. However, its penetration into clinic has yet to prevail. One technical bottleneck is high throughput proteomic analysis of clinical specimens from (multi-center) cohort studies, whereas integrative analysis of proteomics data with clinical and other omics data poses another technical challenge. Moreover, the comprehension of the unmet clinical needs by the mass spectrometrists, and the understanding of the progresses and limitations of cutting-edge proteomic techniques by the clinicians are non-trivial. This symposium gathers experts from clinical medicine, proteomics and beyond, with a goal of building a complete picture of the MS-based clinical proteomics: the current status and the perspective for future development.
